just doubled again my $SGMO position

RT @Longroaderstar: $sgmo $vygr Payload failure, not capsid.

RT @ExelixisInc: ATTN Investors: $EXEL Q4 and Full Year 2024 earnings announcement details available here: https:/…

RT @SchoolyardPS7: @Franca_ole @yusufhameed It was a terrible article. Poorly researched. I wrote a lengthy reply in the article under jeff…

@yusufhameed I can't really take this SA article seriously because the excellent eGFR values in STAAR were not mentioned by the author. $SGMO

Market research companies expect enzyme replacement therapy to increase in sales by 2030. I don't think so, because successful $SGMO gene therapy will make ERT unnecessary.

@JungleJorge2 then you have more than doubled your investment so far – what is your problem? A rollercoaster ride in the green area is bearable, isn't it?

$LIPO reported topline data from its Phase 2a trial of LP-310, an oral rinse for treating oral lichen planus. LP-310 showed a strong safety profile with no serious adverse events or dropouts, and demonstrated statistically significant improvements at weeks 1, 4, and 6.

$INAB announced Phase 1 data for its allogeneic gamma-delta T cell therapy, INB-100, in AML patients post-transplant. All treated patients remain in complete remission with a median follow-up of 20.1 months, achieving 100% one-year progression-free and overall survival, outperforming real-world controls. Durable remissions were supported by persistent gamma-delta T cells and a manageable safety profile.

@GothamGirl_1 @SangamoTx @sandymacrae23 @JohnMarkels Both are true, but the liquidity problem should come to an end with the announcement of a collaboration with ST-920.

"AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study ...Many other biotechs are seeking to advance a treatment for Fabry. $SGMO, for example, announced in October 2024 that it had aligned with the FDA on an accelerated pathway for its gene therapy isaralgagene civaparvovec. The “successful” discussions with the regulator could speed up the treatment’s time-to-market by three years, the biotech said at the time."

That is what FD sufferers are waiting for. $SGMO #isaralgagene_civaparvovec (ST-920) works: "Significant improvements continued to be observed in the short form-36 (SF-36) quality of life (QoL) scores reported, with a mean change in General Health score of 10.6 (p=0.0020). For context, a three- to five-point change on any SF-36 score is considered a minimally clinically important difference."

$AXSM reached a settlement with Teva Pharmaceuticals, resolving patent litigation over Axsome’s AUVELITY product. The dispute arose after Teva sought FDA approval to market a generic version of AUVELITY before Axsome’s patents expired.

$BDRX announced today that the FDA has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).

RT @DaveAudet: This eGFR result is across the first 23 patients including all the lower dose patients but not all the highest dose cohort y…

"expect Fabry deal in 1Q25" $SGMO first quarter still lasts 50 days – that's the blink of an eye. How much will the upfront payment be / acceptance of the application for approval / approval of ST-920 by FDA? my guess (in m$) 150/50/150 What do you think?

RT @zeusPharma: @lipa0902 The main reason I am bullish on $SGMO is because of ST-920. The recent update provides life-changing data for Fab…

Do you really know your way around pharmaceutical research? For example, in 2024, Roche invested around 14 billion US dollars in R&D, which is about 22% of its total sales of 64.17 billion US dollars. However, most new drugs are recruited through in-licensing. In relation to the resources used, the $SGMO output is excellent.

RT @pick1998_2: $SGMO the data of Fabry disease gene therapy is amazingly good. Durable, and safer than ERT. BLA late this year. I will s…

RT @BiotechAnalysst: Cowen $SGMO impressive, durable efficacy on eGFR α-GalA activity plasma lysoGb3+PROs stat sig interim 1yr mean eGFR sl…